XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
Recent Transactions, Telavant Disposition (Details) - USD ($)
$ in Thousands
2 Months Ended 3 Months Ended 8 Months Ended 9 Months Ended
Dec. 14, 2023
Dec. 14, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 14, 2023
Dec. 31, 2023
Dec. 31, 2022
Consideration [Abstract]                
Gain on sale of Telavant net assets       $ 5,348,410 $ 0   $ 5,348,410 $ 0
Telavant Holdings, Inc. [Member]                
Consideration [Abstract]                
Pretax loss   $ (27,300) $ (89,400)     $ (71,100)    
Telavant Holdings, Inc. [Member] | RSL [Member]                
Telavant Disposition [Abstract]                
Ownership percentage 75.00% 75.00%       75.00%    
Consideration [Abstract]                
Gain on sale of Telavant net assets       $ 5,300,000     $ 5,300,000  
Telavant Holdings, Inc. [Member] | Pfizer [Member]                
Telavant Disposition [Abstract]                
Ownership percentage 25.00% 25.00%       25.00%    
Roche Transaction [Member]                
Consideration [Abstract]                
Upfront cash payment $ 7,100,000              
Consideration to be received from milestone 150,000              
Roche Transaction [Member] | RSL [Member]                
Consideration [Abstract]                
Upfront cash payment 5,234,373              
Consideration to be received from milestone 110,000              
Carrying amount of noncontrolling interest derecognized 87,500 $ 87,500       $ 87,500    
Total consideration 5,321,873 5,321,873       5,321,873    
Assets sold 3,253 3,253       3,253    
Liabilities transferred 29,790 29,790       29,790    
Net liabilities sold (26,537) $ (26,537)       $ (26,537)    
Gain on sale of Telavant net assets $ 5,348,410